These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 25431336)

  • 21. Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study).
    Vardeny O; Wu DH; Desai A; Rossignol P; Zannad F; Pitt B; Solomon SD;
    J Am Coll Cardiol; 2012 Nov; 60(20):2082-9. PubMed ID: 23083787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hemoconcentration is a good prognostic predictor for clinical outcomes in acute heart failure: data from the Korean Heart Failure (KorHF) Registry.
    Oh J; Kang SM; Hong N; Youn JC; Han S; Jeon ES; Cho MC; Kim JJ; Yoo BS; Chae SC; Oh BH; Choi DJ; Lee MM; Ryu KH
    Int J Cardiol; 2013 Oct; 168(5):4739-43. PubMed ID: 23958420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).
    Shah AN; Mentz RJ; Gheorghiade M; Kwasny MJ; Fought AJ; Zannad F; Swedberg K; Maggioni AP; Konstam MA
    Am J Cardiol; 2012 Dec; 110(12):1803-8. PubMed ID: 22999071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
    Anand IS; Rector TS; Kuskowski M; Adourian A; Muntendam P; Cohn JN
    Eur J Heart Fail; 2013 May; 15(5):511-8. PubMed ID: 23291728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial.
    Mentz RJ; Chung MJ; Gheorghiade M; Pang PS; Kwasny MJ; Ambrosy AP; Vaduganathan M; O'Connor CM; Swedberg K; Zannad F; Konstam MA; Maggioni AP
    Am Heart J; 2012 Dec; 164(6):884-92.e2. PubMed ID: 23194489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction.
    O'Connor CM; Mentz RJ; Cotter G; Metra M; Cleland JG; Davison BA; Givertz MM; Mansoor GA; Ponikowski P; Teerlink JR; Voors AA; Fiuzat M; Wojdyla D; Chiswell K; Massie BM
    Eur J Heart Fail; 2012 Jun; 14(6):605-12. PubMed ID: 22535795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial.
    Payvar S; Spertus JA; Miller AB; Casscells SW; Pang PS; Zannad F; Swedberg K; Maggioni AP; Reid KJ; Gheorghiade M;
    Eur J Heart Fail; 2013 Dec; 15(12):1382-9. PubMed ID: 23858000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.
    Cohen-Solal A; McMurray JJ; Swedberg K; Pfeffer MA; Puu M; Solomon SD; Michelson EL; Yusuf S; Granger CB;
    Eur Heart J; 2008 Dec; 29(24):3022-8. PubMed ID: 18987098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure--association with signs and symptoms, hospitalization duration, and 60-day outcomes.
    Cotter G; Metra M; Weatherley BD; Dittrich HC; Massie BM; Ponikowski P; Bloomfield DM; O'Connor CM
    Cardiology; 2010; 115(1):29-36. PubMed ID: 19844102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study.
    Biegus J; Hillege HL; Postmus D; Valente MA; Bloomfield DM; Cleland JG; Cotter G; Davison BA; Dittrich HC; Fiuzat M; Givertz MM; Massie BM; Metra M; Teerlink JR; Voors AA; O'Connor CM; Ponikowski P
    Eur J Heart Fail; 2016 Jul; 18(7):830-9. PubMed ID: 27170455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study.
    Cotter G; Metra M; Davison BA; Senger S; Bourge RC; Cleland JG; Jondeau G; Krum H; O'Connor CM; Parker JD; Torre-Amione G; van Veldhuisen DJ; Milo O; Kobrin I; Rainisio M; McMurray JJ; Teerlink JR;
    Eur J Heart Fail; 2014 Dec; 16(12):1362-71. PubMed ID: 25371147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: an individual patient data meta-analysis(†): Meta-Analysis Global Group in Chronic heart failure (MAGGIC).
    Rusinaru D; Tribouilloy C; Berry C; Richards AM; Whalley GA; Earle N; Poppe KK; Guazzi M; Macin SM; Komajda M; Doughty RN;
    Eur J Heart Fail; 2012 Oct; 14(10):1139-46. PubMed ID: 22782968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial.
    Gheorghiade M; Rossi JS; Cotts W; Shin DD; Hellkamp AS; Piña IL; Fonarow GC; DeMarco T; Pauly DF; Rogers J; DiSalvo TG; Butler J; Hare JM; Francis GS; Stough WG; O'Connor CM
    Arch Intern Med; 2007 Oct; 167(18):1998-2005. PubMed ID: 17923601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function.
    Weatherley BD; Cotter G; Dittrich HC; DeLucca P; Mansoor GA; Bloomfield DM; Ponikowski P; O'Connor CM; Metra M; Massie BM;
    J Card Fail; 2010 Jan; 16(1):25-35. PubMed ID: 20123315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).
    Wong CM; Hawkins NM; Jhund PS; MacDonald MR; Solomon SD; Granger CB; Yusuf S; Pfeffer MA; Swedberg K; Petrie MC; McMurray JJ
    J Am Coll Cardiol; 2013 Nov; 62(20):1845-54. PubMed ID: 23850914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial.
    Greene SJ; Maggioni AP; Fonarow GC; Solomon SD; Böhm M; Kandra A; Prescott MF; Reimund B; Hua TA; Lesogor A; Zannad F; Gheorghiade M;
    Eur J Heart Fail; 2015 Jan; 17(1):98-108. PubMed ID: 25597870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials.
    Latini R; Gullestad L; Masson S; Nymo SH; Ueland T; Cuccovillo I; Vårdal M; Bottazzi B; Mantovani A; Lucci D; Masuda N; Sudo Y; Wikstrand J; Tognoni G; Aukrust P; Tavazzi L;
    Eur J Heart Fail; 2012 Sep; 14(9):992-9. PubMed ID: 22740508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of blood pressure and its evolving changes with the survival of patients with heart failure.
    Grigorian-Shamagian L; Gonzalez-JuAnatey JR; Vazquez R; Cinca J; Bayes-Genis A; Pascual D; Fernandez-Palomeque C; Bardaji A; Almendral J; Nieto V; Macaya C; Jimenez RP; de Luna AB;
    J Card Fail; 2008 Sep; 14(7):561-8. PubMed ID: 18722321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
    Vaduganathan M; Ambrosy AP; Greene SJ; Mentz RJ; Subacius HP; Maggioni AP; Swedberg K; Nodari S; Zannad F; Konstam MA; Butler J; Gheorghiade M;
    Circ Heart Fail; 2012 Nov; 5(6):750-8. PubMed ID: 23051949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
    O'Connor CM; Abraham WT; Albert NM; Clare R; Gattis Stough W; Gheorghiade M; Greenberg BH; Yancy CW; Young JB; Fonarow GC
    Am Heart J; 2008 Oct; 156(4):662-73. PubMed ID: 18926148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.